Cocktail for the heart
During a multicenter randomized clinical trial of cardiopoietic stem cell therapy for heart failure (C-CURE), developed by researchers at the Mayo Clinic under the leadership of Dr. Andre Terzic, an international team of specialists from Belgium, Switzerland and Serbia demonstrated promising results.
As part of the study, patients in the control group received standard treatment for heart failure, while patients in the experimental group, in addition to standard therapy, were injected with cardiopoietic stem cells, which are the first biotherapeutic drug in their class.
This additional therapy involved taking bone marrow from the patient's iliac bone, isolating stem cells from it and culturing them with the addition of a specially developed protein cocktail that ensures the differentiation of stem cells in the cardiogenic direction. The resulting cardiopoietic stem cells were injected into the patient's heart.
As a result, noticeable improvements were observed in all patients of the experimental group. In addition to the improvement in the pumping function of the heart recorded within six months after the introduction of the cells, patients demonstrated increased endurance, including an increase in walking distances.
Moreover, six months after the experimental therapy, the volume of the ejection fraction of the heart increased by 7%, while no significant changes in this indicator were recorded in patients of the control group. According to experts, given the relatively short period of time that has passed since the introduction of cells, this improvement is very significant, which distinguishes experimental therapy from the most effective modern approaches available to doctors.
The Mayo Clinic has signed a contract with the Belgian company Cardio3 Biosciences to improve its cocktail for cardiogenic cell differentiation, bring its production volumes to the industrial level and conduct further clinical studies.
Evgeniya Ryabtseva
Portal "Eternal youth" http://vechnayamolodost.ru based on the materials of the Mayo Clinic:
Mayo Clinic: Cardiopoietic 'Smart' Stem Cells Show Promise in Heart Failure Patients.
15.04.2013